Test Price
2,800 AED✅ Home Collection Available
DNM2 Gene Centronuclear Myopathy Type 1 Genetic Test – DNA Labs UAE
Executive Summary & Core Metrics
Comprehensive Molecular Diagnosis for Centronuclear Myopathy Type 1
- 99.9% analytical sensitivity via ISO 9001:2015 certified next-generation sequencing workflow.
- VIP mobile phlebotomy with temperature-controlled cold-chain home collection available daily from 8 AM to 11 PM.
- Post-test genetic counselling by DHA-licensed Consultant Medical Genetics.
- Direct insurance coverage verification via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
This assay delivers full-gene sequencing of DNM2 by next-generation technology with orthogonal Sanger confirmation, enabling definitive molecular diagnosis of centronuclear myopathy type 1 — a rare congenital myopathy characterised by progressive muscle weakness and characteristic central nuclei on histopathology.
| Feature | DNA Labs UAE Test | Closest Alternative |
|---|---|---|
| Sequencing Method | NGS full DNM2 gene coverage + orthogonal Sanger confirmation | Limited hotspot panel or single‑exon testing |
| Turnaround Time | 3–4 weeks from sample receipt | 6–8 weeks |
| Price | 2,800 AED – inclusive of pre‑ and post‑test genetic counselling | 3,500–4,500 AED |
| Home Collection | VIP mobile phlebotomy, ISO cold‑chain, 8 AM–11 PM daily | Limited or unavailable |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403
“A pathogenic DNM2 variant must always be interpreted within the complete clinical and family context — not every alteration predicts early onset or severe progression. I encourage families to use this genomic information as a guide for surveillance and counselling, not as a standalone prognosis, and to correlate results with a neurologist experienced in congenital myopathies.”
Advisory – Medication and Treatment Plan Integrity
Do not discontinue or modify any prescribed medication or therapeutic intervention based solely on this genetic finding without direct consultation with the treating physician.
Patient Safety – Exclusion Criteria & Emergency Indicators
- Do not collect the sample if the patient is critically ill or haemodynamically unstable; deferral is clinically appropriate.
- Minors under 18 years require explicit parental or legal guardian consent in compliance with Federal Decree-Law No. 4 of 2016 on Medical Liability.
- If the patient experiences sudden worsening of limb or respiratory muscle strength, difficulty swallowing, or altered consciousness, seek emergency medical care immediately.
- This test is not validated for carrier screening in asymptomatic minors without prior genetic counselling.
Patient FAQ & Clinical Guidance
1. What condition does the DNM2 gene test diagnose and who should be tested?
This test identifies pathogenic variants in the DNM2 gene that cause centronuclear myopathy type 1, a congenital myopathy presenting with progressive muscle weakness, hypotonia, and often respiratory involvement. It is indicated for individuals with clinical features suggestive of a congenital myopathy, particularly when muscle biopsy shows central nuclei, and for family members after a proband diagnosis.
2. How is the DNA sample collected and what are the logistics for home collection in the UAE?
A certified mobile phlebotomist collects a peripheral whole blood sample or a painless FTA card dried blood spot. The specimen is preserved in a validated ISO-compliant temperature-controlled cold chain from your residence directly to the DNA Labs UAE processing facility. Home collection is available daily from 8 AM to 11 PM.
3. How accurate is the NGS analysis and what does a positive result mean for my child?
The assay achieves 99.9% analytical sensitivity for single nucleotide variants and copy number changes across the entire DNM2 coding region. A positive result confirms the molecular diagnosis of centronuclear myopathy type 1, enabling targeted clinical surveillance, respiratory and cardiac monitoring, and informed family planning with the support of a Consultant Medical Genetics.
UAE Regulatory & Data Privacy Adherence
- Licensed by the Dubai Health Authority (DHA) – Facility License Number 1143.
- All genetic data handling complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
- Diagnostic workflows are ISO 9001:2015 certified (Cert: INT/EGQ/2509DA/3139), ensuring stringent quality management.
- Pre- and post-test genetic counselling is delivered by DHA-licensed professionals; tele-counselling is available via WhatsApp at +971 54 548 8731.
Clinical & Logistical Metadata
| Test Name | DNM2 Gene Centronuclear Myopathy Type 1 Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks from sample receipt |
| Sample Type / Matrix | Peripheral whole blood or FTA card – VIP mobile phlebotomy with temperature-controlled cold-chain home collection (daily 8 AM – 11 PM) |
| Methodology Used | Next-Generation Sequencing (NGS) with orthogonal Sanger confirmation |
| ICD-10-CM Code | G71.2 |
| LOINC Code | 81307-5 |
| DHA Facility License & Laboratory Address | License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians